TAK N Stock Overview
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
Takeda Pharmaceutical Company Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥240.49 |
52 Week High | JP¥303.97 |
52 Week Low | JP¥239.70 |
Beta | 0.54 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -29.89% |
5 Year Change | -32.82% |
Change since IPO | -22.42% |
Recent News & Updates
Recent updates
Shareholder Returns
TAK N | MX Pharmaceuticals | MX Market | |
---|---|---|---|
7D | 0% | -6.1% | -2.2% |
1Y | n/a | -18.5% | 0.6% |
Return vs Industry: Insufficient data to determine how TAK N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TAK N performed against the MX Market.
Price Volatility
TAK N volatility | |
---|---|
TAK N Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.5% |
Market Average Movement | 3.8% |
10% most volatile stocks in MX Market | 6.1% |
10% least volatile stocks in MX Market | 1.7% |
Stable Share Price: TAK N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TAK N's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1781 | 49,095 | Christophe Weber | www.takeda.com |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands.
Takeda Pharmaceutical Company Limited Fundamentals Summary
TAK N fundamental statistics | |
---|---|
Market cap | Mex$700.10b |
Earnings (TTM) | Mex$19.60b |
Revenue (TTM) | Mex$458.55b |
35.7x
P/E Ratio1.5x
P/S RatioIs TAK N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TAK N income statement (TTM) | |
---|---|
Revenue | JP¥4.17t |
Cost of Revenue | JP¥1.34t |
Gross Profit | JP¥2.82t |
Other Expenses | JP¥2.65t |
Earnings | JP¥178.22b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
Earnings per share (EPS) | 113.59 |
Gross Margin | 67.76% |
Net Profit Margin | 4.27% |
Debt/Equity Ratio | 69.2% |
How did TAK N perform over the long term?
See historical performance and comparison